CGTLive’s Weekly Rewind – September 29, 2023


Review top news and interview highlights from the week ending September 29, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Alternative Polyadenylation May Play a Role in ALS Disease Pathogenesis

Sebastian Michels, MD, a postdoctoral fellow and member of the La Spada Lab at University of California, Irvine, discussed how his lab’s findings may open the door to developing RNA therapeutics for ALS.

2. Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs

The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy.

3. Precigen Trying Its Hand at CAR-T for Ovarian Cancer in Phase 1/1b Trial

Notably, the trial is assessing intravenous administration of PRGN-3005 against intraperitoneal administration in 2 separate cohorts.

4. J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials

The associate professor at MD Anderson Cancer Center discussed the upcoming trial of NY-ESO-1 TCR/IL-15 NK cell therapy for SS and MRCLS.

5. Abeona's RDEB Cell Therapy Up for Review

Abeona has submitted a BLA for its EB-101 cell therapy.

Related Videos
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024
Omid Hamid, MD
© 2024 MJH Life Sciences

All rights reserved.